Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

CTA-012 shows promise in MS disease model

June 12, 2006

Provigil indications amended in U.K.

June 12, 2006

Escitalopram, but not duloxetine, affects sexual function in patients with depression

June 12, 2006

Serotonin 5-HT6 antagonist PRX-07034 begins phase I study

June 9, 2006

Enrollment opens in phase II study of AL-208 for CABG-associated MCI

June 9, 2006

Data from trial of eszopiclone in insomniac patients with depression further analyzed

June 9, 2006

PF-670462: new potent CKIe inhibitor evokes phase delays

June 9, 2006

Progesterone may be of benefit in treating brain trauma

June 9, 2006

Betaferon approved in Europe as first-line treatment for earliest stages of MS

June 8, 2006

Abilify launched in Japan

June 8, 2006

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 7, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 7, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Science in 2025: the best of the rest
BioWorld Science
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...